(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 December 2006 (21.12.2006)

PCT

(10) International Publication Number
WO 2006/134485 A1

(51) International Patent Classification:
C07D 491/10 (2006.01) *A61K 31/343* (2006.01)

(21) International Application Number:
PCT/IB2006/001624

(22) International Filing Date: 8 June 2006 (08.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/691,905 17 June 2005 (17.06.2005) US

(71) Applicant *(for JP only)*: **PFIZER JAPAN INC.** [JP/JP]; Shinjuku Bunka Quint Bldg., 3-22-7, Yoyogi, Shibuya-ku, Tokyo 151-8589 (JP).

(71) Applicant *(for all designated States except JP, US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HASHIZUME, Yoshinobu** [JP/JP]; Pfizer Japan, 2, Aza 5 Gochi, Taketoyo-cho, Chita-gun, Aichi 470-2393, Nagoya (JP). **HIROTA, Masako** [JP/JP]; Pfizer Japan, 2, Aza 5 Gochi, Taketoyo-cho, Chita-gun, Aichi 470-2393, Nagoya (JP). **KOIKE, Hiroki** [JP/JP]; Pfizer Japan, 2, Aza 5 Gochi, Taketoyo-cho, Chita-gun, Aichi 470-2393 (JP). **MATSUMOTO, Yukari** [JP/JP]; Pfizer Japan, 2, Aza 5 Gochi, Taketoyo-cho, Chita-gun, Aichi 470-2393 (JP). **MIHARA, Sachiko** [JP/JP]; Pfizer Japan, 2, Aza 5 Gochi, Taketoyo-cho, Chita-gun, Aichi 470-2393 (JP). **NAKAMURA, Hiroshi** [JP/JP]; Pfizer Japan, 2, Aza 5 Gochi, Taketoyo-cho, Chita-gun, Aichi 470-2393 (JP).

(74) Agents: **GROVER, F., Fuller, Jr.** et al.; c/o DROUIN, Stéphane, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

[Continued on next page]

(54) Title: ALPHA-(ARYL-OR HETEROARYL-METHYL)-BETA-PIPERIDINOPROPANOIC ACID COMPOUNDS AS ORL1-RECEPTOR ANTAGONISTS



(I)

(57) Abstract: This invention provides the compounds of formula (I): or a pharmaceutically acceptable ester or salt thereof, wherein R^1 and R^2 independently represent hydrogen or the like; R^3 represents aryl or the like; -X-Y- represents -CH_2O- or the like; and n represents 0, 1 or 2. These compounds have ORL1 -receptor antagonist activity; and therefore, are useful to treat diseases or conditions such as pain, various CNS diseases etc.

WO 2006/134485 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.